Ghent University Academic Bibliography

Your filters: cql: author="Kermode, Allan G." or (type any "bookEditor issueEditor" and editor="Kermode, Allan G.")

Add to list
- Journal Article
- A1
- open access
Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapies

Wei Z. Yeh, Anneke Van Der Walt, Olga G. Skibina, Tomas Kalincik, Raed Alroughani, Allan G. Kermode, Marzena J. Fabis-Pedrini, William M. Carroll, Jeannette Lechner-Scott, Cavit Boz, et al.

(2024) NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 11(6).
Add to list
- Journal Article
- A1
- open access
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

Anoushka P. Lal, Yi Chao Foong, Paul G. Sanfilippo, Tim Spelman, Louise Rath, David Levitz, Marzena Fabis-Pedrini, Matteo Foschi, Mario Habek, Tomas Kalincik, et al.

(2024) JOURNAL OF NEUROLOGY. 271. p.5813-5824
Add to list
- Journal Article
- A1
- open access
Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

Chao Zhu, Tomas Kalincik, Dana Horakova, Zhen Zhou, Katherine Buzzard, Olga Skibina, Raed Alroughani, Guillermo Izquierdo, Sara Eichau, Jens Kuhle, et al.

(2023) JAMA NEUROLOGY. 80(7). p.739-748
Add to list
Redefining the Multiple Sclerosis Severity Score (MSSS) : the effect of sex and onset phenotype

Yuan Zhou, Suzi B. Claflin, Jim Stankovich, Ingrid van der Mei, Jr. Simpson, Steve, Richard H. Roxburgh, Tomas Kalincik, Leigh Blizzard, Alessandra Lugaresi, Raed Alroughani, et al.

(2019) MULTIPLE SCLEROSIS JOURNAL. 26(13). p.1765-1774

Academic Bibliography

Disease activity in pregnant and postpartum women with multiple sclerosis receiving ocrelizumab or other disease-modifying therapies

A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic

Comparison between dimethyl fumarate, fingolimod, and ocrelizumab after natalizumab cessation

Redefining the Multiple Sclerosis Severity Score (MSSS) : the effect of sex and onset phenotype

Contents

Support

Contact